| Literature DB >> 28500019 |
Josephine Norquist1, Diana Chirovsky2, Teja Munshi2, Chloe Tolley3, Charlotte Panter3, Adam Gater3.
Abstract
BACKGROUND: Patient-reported outcome (PRO) instruments are important tools for monitoring disease activity and response to treatment in clinical trials and clinical practice. In recent years, there have been movements away from traditional pen-and-paper PROs towards electronic administration. When using electronic PROs (ePROs), evidence that respondents complete ePROs in a similar way to their paper counterparts provides assurance that the two modes of administration are comparable or equivalent. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 item (EORTC QLQ-C30) and associated disease-specific modules are among the most widely used PROs in oncology. Although studies have evaluated the comparability and equivalence of electronic and original paper versions of the EORTC QLQ-C30, no such studies have been conducted to date for the head and neck cancer specific module (EORTC QLQ-H&N35).Entities:
Keywords: EORTC QLQ-C30; comparability; ePRO; head and neck cancer; quality of life questionnaire
Year: 2017 PMID: 28500019 PMCID: PMC5446668 DOI: 10.2196/cancer.7202
Source DB: PubMed Journal: JMIR Cancer ISSN: 2369-1999
Figure 1Interview methodology.
Study inclusion/exclusion criteria.
| Study | Criteria | ||
| Inclusion | Participant is at ≥18 years of age. | ||
| Participant is willing and able to provide written informed consent and attend and participate in a 1-hour interview. | |||
| Participant is literate in English and verbally fluent in English. | |||
| Participant has confirmed H&N cancer or has been in remission for up to 3 yearsa. | |||
| The eligible primary tumor locations included pharynx (oropharynx, hypopharynx, epipharynx, parapharynx, nasopharynx), oral cavity, and larynx.b | |||
| Participant has a current ECOG performance status of grade 0-2.b | |||
| Exclusion | Participant has brain metastases or intracranial extension of the tumor with cognitive impairment. | ||
| Participant has significant difficulty hearing, reading, or speaking. | |||
| Participant has an uncontrolled psychiatric condition or mental condition (eg, schizophrenia, bipolar disorder) or severe physical, neurological, or cognitive deficits rendering the participant unable to understand study scope or participate in a 1-hour interview. | |||
aConsistent with disease criterion defined in validation studies of the H&N module [19].
bParticipants recruited via the patient advocacy group were asked to provide their tumor location using a descriptive diagram, and ECOG status was estimated based on participant self-report.
Demographic and clinical characteristics of participants.
| Characteristic | Participants, n | |
| 51.5 (34-80) | ||
| <65 years | 9 | |
| >65 years | 1 | |
| Male | 5 | |
| Female | 5 | |
| Live alone | 2 | |
| Live with husband/wife/partner | 4 | |
| Live with parents/family or friends | 4 | |
| Hispanic or Latino | 1 | |
| Not Hispanic or Latino | 9 | |
| Caucasian | 7 | |
| Multiracial | 3 | |
| High school diploma | 4 | |
| Some years of college | 1 | |
| University/college degree (2 or 4 year) | 4 | |
| Graduate or professional degree | 1 | |
| Working full or part-time | 6 | |
| Retired | 2 | |
| Not working due to head and neck cancer | 2 | |
| Desktop | 9 | |
| Tablet | 7 | |
| Mobile phone | 8 | |
| All the time | 8 | |
| Sometimes | 1 | |
| Rarely | 1 | |
| <6 months | 3 | |
| 6-12 months | 1 | |
| 1-2 years | 2 | |
| 2-3 years | 2 | |
| 3-5 years | 2 | |
| Oropharynx | 2 | |
| Hypopharynx | 1 | |
| Epipharynx | 1 | |
| Larynx | 3 | |
| Oral cavity | 3 | |
| Stage I | 4 | |
| Stage II | 2 | |
| Stage III | 1 | |
| Stage IVa-b | 1 | |
| Stage IVc | 2 | |
| Yes | 2 | |
| No | 8 | |
| Yes | 3 | |
| No | 7 | |
| 0 | 6 | |
| 1 | 1 | |
| 2 | 3 | |
| Concurrent systemic therapy plus radiation | 1 | |
| Radiation | 1 | |
| Immunotherapy | 1 | |
| None | 6 | |
| Othera | 1 | |
aParticipant due to start a trial in 2 weeks.
Figure 2Qualitative comparability of EORTC QLQ-H&N35 (by item).
Figure 3Qualitative comparability of EORTC QLQ-H&N35 (by participant).